The global neuroendocrine carcinoma treatment market was valued US$ 1.7 Bn in 2022, and is expected to exhibit a CAGR of 8% during the forecast period (2019 – 2029).Prominently driven by collaborative strategies for speedy research of drugs for neuroendocrine carcinoma treatment, the market is set for an impressive.
AGOURA HILLS, Calif., Aug. 17, 2022 Oncotelic Therapeutics, Inc. , developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that. | August 17, 2022
The global neuroendocrine carcinoma treatment market was valued US$ 1.7 Bn in 2022, and is expected to exhibit a CAGR of 8% during the forecast period (2022 – 2029).Prominently driven by collaborative strategies for speedy research of drugs for neuroendocrine carcinoma treatment, the market is set for an impressive.
JERSEY CITY, N.J., July 6, 2022 /PRNewswire/ InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Vascular Disrupting Agents Market By Indications